Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2005-06-21
2005-06-21
Le, Long V. (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007800, C435S069700, C436S015000, C436S548000, C436S547000
Reexamination Certificate
active
06908738
ABSTRACT:
The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2C19 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 2C19 and lack of specific binding to other human cytochrome P450s. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2C19, and in methods of measuring P450 2C19 levels in individuals relative to P450 2C19 levels in a control population.
REFERENCES:
patent: 5939530 (1999-08-01), Gelboin et al.
patent: 6060253 (2000-05-01), Gelboin et al.
Biochemistry 29(37): 8509-8517.
Trends in Genetics 15(4): 132-133.
Trends in Genetics 12(10) 425-427.
Trends in Biotech. 18(1): 34-39.
Cheng et al., (1984) Detection and purification of cytochromes P-450 in animal tissues with monoclonal antibodiesJBC259:12279-12284.
Crespi et al., (1989) Transfection of a human cytochrome P-450 gene into the human lymphoblastoid cell line, AHH-1, and use of the recombinant cell line in gene mutation assaysCarcinogenesis10:295-301.
Crespi CL (1995) Xenobiotic Metabolizing Human Cells as Tools for Pharmacological and Toxicological Research.Adv in Drug Research26:180-216.
Crespi,CL and BW Penman (1997) Use of cDNA Expressed Human Cytochrome P450 Enzymes to Study Potential Drug-Drug Interactions.Adv in Pharmacology43:171-188.
Edwards et al., (1998) Development of a Comprehensive Panel of Antibodies Against the Major Xenobiotic Metabolizing Forms of Cytochrome P450 in Humans.Gene Expression and Development56(3):377-387.
Eichelbaum et al., (1992) Genetically determined differences in drug metabolism as a risk factor in drug toxicity.Toxicology Letters64/65:155-122.
Fujino et al., (1982) Phenotyping of Cytochromes P-450 in Human Tissues with Monoclonal Antibodies.Proc Natl Acad Sci USA79:3682-3686.
Gelboin (1993) Cytochrome P450 and Monoclonal Antibodies.Pharmacol Rev45:413-453.
Gelboin et al., (1995) Inhibitory and Non Inhibitory Monoclonal Antibodies to Human Cytochrome P450 3A3/4.Biochem Pharmacol50:1841-1850.
Gelboin et al., (1996) Inhibitory and Noninhibitory Monoclonal Antibodies to Human Cytochrome P450 2E1.Chem Res Toxicl9:1023-1030.
Gelboin et al., (1997) A Monoclonal Antibody Inhibitory to Human P450 2D6: A Paradigm for use in Combinatorial Determination of Individual P450 role in Specific Drug Tissue Metabolism.Pharmacogenetics7:469-477.
Gelboin HV, et al., (1998) Monoclonal Antibodies to Cytochrome P450 in Methods in Molecular Biology: Cytochrome P450 Protocols. (IR Phillips and EA Shephard, eds) pp 227-237, Humana Press Inc., Totowa, New Jersey.
Gelboin et al., (1999) Inhibitory Monoclonal Antibodies to Human Cytochrome P450 Enzymes: A New Avenue for Drug Discovery.Trends Pharmacol Sci20(11):432-438.
Gonzalez et al., (1988) The molecular biology of cytochrome P450s.Pharmacol. Rev.40:243-288.
Gonzalez et al., (1991) Expression of mammalian cytochrome P450 using baculovirusMeth. Enzymol.206:93-99.
Gonzalez and J.Idle, (1994) Pharmacogenetic phenotyping and genotyping. Present status and future potential.Clin. Pharmacokin.26:59-70.
Gonzalez, FJ and KR Korzekwa (1995) Human Cytochromes P450 Expression Systems.Annu Rev Pharmacol Toxicol35:369-390.
Ioannides (1996) Cytochromes P450 Metabolic and Toxicological Aspects. CRC Press, New York.
Krausz et al., (2000) An Inhibitory Monoclonal Antibody to Human Cytochrome P450 that Specifically Binds and Inhibits P4502C9II, an Allelic Variant of P4502C9 Having a Single Amino Acid Change Arg144 Cys.Xenobiotica30:619-625.
Nebert et al., (1991) The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclatureDNA&Cell Biology10:1-14.
Nelson et al., (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclaturePharmacogenetics6:1-42.
Omura, T. and R. Sato (1964) The Carbon Monoxide-Binding Pigment of Liver Microsomes. I. Evidence for its Hemoprotein Nature.J Biol Chem239:2370-2378.
Park et al., (1982) Monoclonal Antibodies That Inhibit Enzyme Activity of 3-Methycholanthracene-Induced Cytochrome P-450.Cancer Res42:1798-1808.
Park et al., (1989) Monoclonal Antibodies to Rat Liver Cytochrome P-450 2c/RLM5 That Regiospecifically Inhibit Steroid Metabolism.Biochem Pharmacol38(18):3067-3074.
Relling et al., (1990) Tolbutamide and Mephenytoin Hydroxylation by Human Cytochrome P450s in the CYP2C Subfamily.J Pharmacol Exp Ther252:442-447.
Remmel and B Burchell (1995) Validation and Use of Cloned Expressed Human Drug Metabolizing Enzymes in Heterogeneous Cells for Analysis of Drug-Drug Interaction.Biochem Pharmacol46:559-566.
Rendic and FJ DiCarlo (1997) Human Cytochrome P450 Enzymes: A Status Report Summarizing Their Reactions Substrates, Inducers and Inhibitors.Drug Metab Rev29:413-580.
Romkes et al., (1991) Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily.Biochemistry30:3247-3255.
Schulz-Utermoehl et al., (2000) Selective and Potent Inhibition of Human CYP2C19 Activity by a Conformationally Targeted Antipeptide Antibody.Drug Metab and Dispos28:715-717.
Shimada et al., (1994) Interindividual Variations in Human Liver Cytochrome P450 Enzymes involved in the Oxidation of Drugs, Carcinogens and Toxic Chemicals: Studies with Liver Microsomes of 30 Japanese and 30 Caucasions.J Pharmacol Exp Ther270:414-423.
Shou et al., (1994) Regio- and stereo-selective metabolism of phenanthrene by twelve cDNA-expressed human, rodent, and rabbit cytochromes P-450.Cancer Lett.83(1-2):305-313.
Streetman et al., (2000) Phenotyping of Drug-Metabolizing Enzymes in Adults: A Review ofIn VivoCytochrome P450 Phenotyping Probes.Pharmacogenetics10:187-216.
Venkatakrishnan et al., (2000) Comparison Between Cytochrome P450 (CYP) Content and Relative Activity Approaches to Scaling from cDNA Expressed CYPs to Human Liver Microsomes: Ratio of Accessory Proteins as Sources of Discrepancies Between the Approaches.Drug Metab and Dispos28(12):1493-1504.
Wester et al., (2000) CYP 2C19 Participates in Tolbutamide Hydroxylation by Human Liver Microsomes.Drug Metab Dispos28(3):354-359.
Yang et al., (1998a) Inhibitory Monoclonal Antibodies to Human Cytochrome P450 1A2: Analysis of Phenacetin o-Deethylation in Human Liver.Pharmacogenetics8:375-382.
Yang et al., (1998b) Inhibitory Monoclonal Antibody to Human Cytochrome P450 2B6.Biochem Pharmacol55:1633-1640.
Yang et al., (1998c) Role of cDNA Expressed Human Cytochromes P450 in the Metabolism of Diazepam.Biochem Pharmacol55:889-896.
Yang et al., (1999) Eight Inhibitory Monoclonal Antibodies Define the Role of Individual P450s in Human Liver Microsomal Diazepam, 7-Ethoxycoumarin and Imipramine Metabolism.Drug Metab Dispos27:102-109.
Gelboin Harry V.
Gonzalez Frank J.
Krausz Kristopher W.
Cassell Nathan S.
Cheu Jacob J.
Le Long V.
National Institute of Health
Townsend & Townsend & Crew LLP
LandOfFree
Agents that bind to and inhibit human cytochrome P450 2C19 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Agents that bind to and inhibit human cytochrome P450 2C19, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agents that bind to and inhibit human cytochrome P450 2C19 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3494177